KNSA - Kiniksa Pharmaceuticals Ltd Stock Price, Fair Value and News

$40.59+0.52 (+1.30%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KNSA Price Action

Last 7 days

-4.6%

Last 30 days

8.3%

Last 90 days

14.3%

Trailing 12 Months

91.7%

KNSA RSI Chart

KNSA Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

84.43

Price/Sales (Trailing)

5.07

EV/EBITDA

57.03

Price/Free Cashflow

29.81

KNSA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KNSA Fundamentals

KNSA Revenue

Revenue (TTM)

598.0M

Rev. Growth (Yr)

61.17%

Rev. Growth (Qtr)

15.34%

KNSA Earnings

Earnings (TTM)

35.9M

Earnings Growth (Yr)

245.24%

Earnings Growth (Qtr)

3.38%

KNSA Profitability

EBT Margin

8.13%

Return on Equity

6.71%

Return on Assets

5.04%

Free Cashflow Yield

3.35%

KNSA Investor Care

Shares Dilution (1Y)

5.05%

Diluted EPS (TTM)

0.46

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	481.2M	529.3M	598.0M	0
2024	301.8M	338.9M	384.1M	423.2M
2023	236.3M	280.8M	248.7M	270.3M
2022	84.0M	129.4M	174.8M	220.2M
2021	0	0	0	38.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

CEO	Mr. Sanj K. Patel
WEBSITE	kiniksa.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	220

Kiniksa Pharmaceuticals Ltd Frequently Asked Questions

What is the ticker symbol for Kiniksa Pharmaceuticals Ltd? What does KNSA stand for in stocks?

KNSA is the stock ticker symbol of Kiniksa Pharmaceuticals Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kiniksa Pharmaceuticals Ltd (KNSA)?

As of Wed Dec 03 2025, market cap of Kiniksa Pharmaceuticals Ltd is 3.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KNSA stock?

You can check KNSA's fair value in chart for subscribers.

Is Kiniksa Pharmaceuticals Ltd a good stock to buy?

The fair value guage provides a quick view whether KNSA is over valued or under valued. Whether Kiniksa Pharmaceuticals Ltd is cheap or expensive depends on the assumptions which impact Kiniksa Pharmaceuticals Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KNSA.

What is Kiniksa Pharmaceuticals Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, KNSA's PE ratio (Price to Earnings) is 84.43 and Price to Sales (PS) ratio is 5.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KNSA PE ratio will change depending on the future growth rate expectations of investors.